Certara, Inc. (NASDAQ:CERT) Short Interest Update

Certara, Inc. (NASDAQ:CERT) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 5,670,000 shares, an increase of 7.4% from the March 15th total of 5,280,000 shares. Currently, 5.2% of the company’s stock are short sold. Based on an average trading volume of 550,800 shares, the short-interest ratio is presently 10.3 days.

Certara Stock Performance

Certara stock traded down $0.37 during mid-day trading on Tuesday, hitting $17.07. The company had a trading volume of 364,968 shares, compared to its average volume of 543,301. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.28. The company’s fifty day moving average is $17.86 and its 200-day moving average is $16.15. Certara has a 12-month low of $11.81 and a 12-month high of $24.96. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of -48.77, a P/E/G ratio of 1.82 and a beta of 1.63.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Thursday, February 29th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. The firm had revenue of $88.01 million during the quarter, compared to analysts’ expectations of $86.80 million. Equities research analysts predict that Certara will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CERT. KeyCorp upgraded Certara from a “sector weight” rating to an “overweight” rating and set a $23.00 price target on the stock in a research note on Wednesday, April 10th. SVB Leerink began coverage on shares of Certara in a research note on Monday, February 26th. They set a “market perform” rating and a $19.00 price objective for the company. JMP Securities initiated coverage on Certara in a research report on Thursday, April 4th. They issued a “market perform” rating on the stock. Leerink Partnrs reiterated a “market perform” rating on shares of Certara in a research note on Monday, February 26th. Finally, UBS Group raised their price objective on Certara from $17.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday, March 1st. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Certara currently has a consensus rating of “Hold” and an average price target of $20.06.

Insider Transactions at Certara

In related news, insider Patrick F. Smith sold 14,427 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total transaction of $243,094.95. Following the sale, the insider now owns 50,091 shares of the company’s stock, valued at $844,033.35. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, SVP Richard M. Traynor sold 6,000 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $18.00, for a total transaction of $108,000.00. Following the transaction, the senior vice president now directly owns 165,368 shares of the company’s stock, valued at $2,976,624. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Patrick F. Smith sold 14,427 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $844,033.35. The disclosure for this sale can be found here. In the last three months, insiders sold 23,427 shares of company stock valued at $405,095. Corporate insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Certara

A number of hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its position in shares of Certara by 584.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,356 shares of the company’s stock valued at $25,000 after buying an additional 1,158 shares in the last quarter. Pineridge Advisors LLC acquired a new stake in shares of Certara in the fourth quarter valued at about $28,000. State of Wyoming increased its stake in shares of Certara by 103.1% during the second quarter. State of Wyoming now owns 2,027 shares of the company’s stock worth $37,000 after purchasing an additional 1,029 shares in the last quarter. Covestor Ltd raised its position in shares of Certara by 14,940.0% during the 3rd quarter. Covestor Ltd now owns 3,760 shares of the company’s stock worth $55,000 after purchasing an additional 3,735 shares during the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in Certara by 42.9% in the 3rd quarter. Advisors Asset Management Inc. now owns 4,710 shares of the company’s stock valued at $68,000 after buying an additional 1,414 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.